FBI NGI August 2020 Fact Sheet Statistics:

• The FBI Next Generation Identification (NGI) database contains the fingerprints of over 136 million individuals (both civil and criminal).
• Over 97% of the Tenprint Rapsheet Request (TPRS) responses were completed within 20 seconds.

Fiscal Year 2020 Average

TRUST IN YOUR WORKFORCE

RELIABLE

RESPONSIVE

COST EFFECTIVE

Fingerprint Background Checks

SAFE • SECURE • FAST

FBI fingerprint-based background checks are increasingly required for U.S. Citizens to live, work or travel overseas in many countries such as China, South Korea, Australia, South Africa, Spain and Israel.

Accurate Biometrics was the first authorized FBI Channeler, to provide access to FBI Identity History Summary Checks (IdHS), or Departmental Orders (556-73). For 20 years we have been a leader in the fingerprint industry with our technology capabilities, expertise and dedicated service to government agencies and private industries.

Our expertise will assist your company:

  • National U.S. Collection Network, over 800 locations in 50 states
  • Fast access to Identity History Summary Checks for Visa

    requirements direct from the FBI CJIS, several delivery options are available including a secure watermarked hard copy of the results

  • SAME DAY International fingerprint card processing
  • Certified AWS GovCloud Hosting Environment for FBI Channeling

For more information, contact...

Will Peterson 
Director of Business Development
708-887-9258​​​​​​​
wpeterson@accuratebiometrics.com
AccurateBiometrics.com

Go to article: Home | Covid-19 and the anti-vax movementGo to article: In this issueGo to article: ContentsGo to article: Accurate Biometrics Company InsightGo to article: Accurate BiometricsGo to article: Contract Pharmaceuticals Limited CanadaGo to article: Mettler Toledo Company InsightGo to article: Mettler ToledoGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: WipotecGo to article: PuroliteGo to article: VEGA AustraliaGo to article: Gerteis Company Insight Go to article: GerteisGo to article: CommentGo to article: US election: Trump and Biden's priorities in the Covid-19 responseGo to article: Covid-19 disruption to trials declines, but recruitment is slowGo to article: Covid-19 vaccine developments across the globeGo to article: Eli Lilly and Regeneron’s EUA bids trigger concerns over available Covid-19 dataGo to article: AstraZeneca’s quick Covid-19 vaccine trial restart splits opinionGo to article: Q&A: Atomwise’s journey from discoverer to developerGo to article: Pfeiffer VacuumGo to article: Koehler eClinicalGo to article: Phoenix Company Insight Go to article: PhoenixGo to article: In DepthGo to article: How to combat vaccine hesitancy in the age of Covid-19Go to article: How Covid-19 has put clinical research’s diversity problem in the spotlight Go to article: No need for animal testing: improving vaccine research with GenoskinGo to article: Gout: drug development for an age-old diseaseGo to article: Treating chronic primary pain in the UKGo to article: Breast cancer breakthrough: could a new therapy silence stubborn TNBC?Go to article: Is quantum computing pharma's next big disruptor?Go to article: MimotopesGo to article: OptelGo to article: Solvias Company Insight Go to article: SolviasGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: In DataGo to article: Inside the dealGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: IWA Consulting Company Insight Go to article: IWA consultingGo to article: Nipro pharmapackagingGo to article: SwiftpakGo to article: EventsGo to article: Next issue